Early neovascular bridging of choroidal neovascularization after ranibizumab treatment

Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1427-30. doi: 10.1007/s00417-009-1143-1. Epub 2009 Jul 21.

Abstract

Background: To report three cases of early choroidal neovascularization (CNV) bridging after ranibizumab treatment.

Methods: Three patients with two separated foci of CNV secondary to age-related macular degeneration (ARMD), pathologic myopia and multifocal choroiditis were treated with monthly injections of ranibizumab por a period of 3 months.

Results: All three cases showed early coalescence across the fovea of the two neovascular foci, already 1 month after the first ranibizumab injection. Best-corrected visual acuity (BCVA) decreased in the three cases more than 20 letters due to early foveal involvement.

Conclusions: Two different foci of CNV show a great tendency to decrease patients' vision because of neovascular bridging with foveal implication.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Choroidal Neovascularization / diagnosis
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / etiology
  • Choroidal Neovascularization / physiopathology
  • Choroiditis / complications*
  • Disease Progression
  • Drug Administration Schedule
  • Female
  • Fluorescein Angiography
  • Follow-Up Studies
  • Fovea Centralis / pathology
  • Fundus Oculi
  • Humans
  • Injections
  • Macular Degeneration / complications*
  • Male
  • Myopia, Degenerative / complications*
  • Ophthalmoscopy
  • Ranibizumab
  • Visual Acuity / drug effects

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Ranibizumab